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Abstract
Objectives: To determine the proportion, characteristics and outcomes of patients who transfer-out from an antiretroviral
therapy (ART) service in a South African township.
Methods: This retrospective cohort study included all patients aged $15 years who enrolled between September 2002 and
December 2009. Follow-up data were censored in December 2010. Kaplan-Meier survival analysis was used to describe time
to transfer-out and cox proportional hazard analysis was used to determine associated risk factors.
Results: 4511 patients (4003 ART-naı¨ve and 508 non-naı¨ve at baseline) received ART during the study period. Overall, 597
(13.2%) transferred out. The probability of transferring out by one year of ART steadily increased from 1.4% in 2002/2004
cohort to 8.9% for the 2009 cohort. Independent risk factors for transfer-out were more recent calendar year of enrolment,
younger age (#25 years) and being ART non-naı¨ve at baseline (i.e., having previously transferred into this clinic from
another facility). The proportions of patients transferred out who had a CD4 cell count ,200 cells/mL and/or a viral load
$1000 copies/mL were 19% and 20%, respectively.
Conclusions:With scale-up of ART over time, an increasing proportion of patients are transferring between ART services and
information systems are needed to track patients. Approximately one-fifth of these have viral loads .1000 copies/mL
around the time of transfer, suggesting the need for careful adherence counseling and assessment of medication supplies
among those planning transfer.
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Introduction
Increasing numbers of patients are receiving antiretroviral
therapy (ART) at health facilities in sub-Saharan Africa and the
World Health Organization (WHO) estimated that 5.1 million
people had started ART in the region by the end of 2010. Of
these, 1.4 million were in South Africa alone [1]. However, as
scale-up has progressed, it has been reported that growing
proportions of patients are not retained long-term within ART
services with losses estimated at approximately 40% of patients
during the first 2 years of therapy [2,3]. Some patients die and
increasing proportions are reported as lost to follow-up (LTFU).
However, while many studies have reported on these two
outcomes [2–7], few have characterised those who transfer-out
to other ART services [7–9].
We have previously reported from an ART service in South
Africa that an increasing proportion of patients enrolling for ART
subsequently transfer-out [7]. The characteristics, risk factors and
immune and virological status of patients transferring out is
unknown. We therefore conducted this detailed analysis of patients
transferring out from a large community based ART service in
Cape Town, South Africa.
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Materials and Methods
Setting
The study was conducted at the Hannan Crusaid Treatment
Centre in Gugulethu township in Cape Town, Western Cape
province, South Africa, which has been described in detail
elsewhere [10,11]. This specialized ART centre is located in
a low-income urban area with an antenatal HIV prevalence
rate of 24% in 2009 and serviced an estimated population of
366 387 people in 2011 [12]. The gender composition was
48.9% male and 51.1% female. According to census 2011,
19.3% of household heads (n = 95406) were unemployed, 24.4%
were not economically active [12]. In general, the Western
Cape is the fastest growing province in South Africa, growing
by 29% between 2006 and 2011 [12]. This influx of people to
the Western Cape highlights the flow of people from rural to
urban areas in search of better job opportunities, infrastructure,
quality of life and public health services. Among 366 387 people
serviced by the clinic, the in-migration streams are predomi-
nantly from the Eastern Cape, followed by outside South Africa
and then the other provinces [12]. The Eastern Cape,
bordering the Western Cape, where much of the migration
originates, has a stagnant economy, inferior infrastructure and
public health care services. As a result, poor individuals tend to
travel back and forth provinces to access better public health
care services in the Western Cape.
Study Cohort
The clinic started providing ART to patients in September 2002
when there were very few other treatment clinics. By the time the
national ART roll-out started in April 2004, there were 16 ART
sites in the Western Cape province, eight of which were based at
primary health care facilities and 2327 patients were then
receiving ART [13]. Thereafter, ART scale-up was rapid and
by June 2012 there were 121 293 patients receiving ART across
179 sites in the Western Cape province. This nation- and
provincial- wide effort to decentralize ART services into more
existing primary health care facilities helped to decrease the
burden of providing ART services at few initial facilities, made
access to ART easier for eligible patients and developed the
capacity of clinicians and/or nurses to initiate and monitor
treatment [14,15].
Treatment outcomes at this ART service were recorded in
a weekly multidisciplinary meeting and these data were entered in
a prospectively maintained ART cohort database on a weekly
basis. Patients were classified as alive and on treatment, dead,
transferred out or LTFU. ‘Transfer-out’ was the term used to refer
to patients who were attending the clinic and whose care was
transferred to another clinic by giving the patient a referral letter.
A decision to transfer care usually arose as a result of either a new
ART service being opened closer to the patient’s home, to
relocation of the patient to another area [7] or upon the patient’s
request.
Clinic- and field-based counsellors supported the ART
service. The counsellors provided educational support, home
visits and liaised with the clinical team. At least one home visit
was conducted pre-ART and another in the first 4 weeks of
ART. Further home visits were conducted for patients classified
as defaulting treatment and those with adherence problems.
The home visits were, however, optional for patients. Home
visits were not conducted for patients who transferred-out as it
was assumed that they had resumed treatment at the new
facility.
Study Design
In this retrospective cohort study, all patients (both ART-naı¨ve
and non-naı¨ve) aged $15 years that were enrolled between
September 2002 and December 2009 were included in the
analysis. Follow up data were censored in December 2010,
providing a minimum of at least one year of potential follow up
and a maximum of 8.3 years.
Data Sources
Data on all patients were obtained from a prospectively
maintained ART cohort database. For each patient, clinical
variables, outcomes, treatment regimens, and laboratory data were
recorded.
Ethics Statement
Routine data collection in the cohort was undertaken with
written informed consent from all patients and ethical approval
from the Research Ethics Committee of the University of Cape
Town (REC REF 359/2002). Additional ethical approval from the
Union’s Ethics Advisory Group (EAG REF: 64/11) was also
obtained.
Study Definitions
‘Patients transferring out’ from this clinic were those who were
referred to another facility to continue ART care as documented
on a referral form or patient notes. The terms ‘ART-naı¨ve’ and
‘ART non-naı¨ve’ referred to patient status at enrolment to the
cohort. The term ‘ART non-naı¨ve’ was used to describe those
patients who had previously transferred in to this cohort from
another treatment site having already started ART. ‘Virological
failure’ was defined as 2 consecutive viral load measurements
.1000 copies/mL among patients who had achieved initial
virological suppression ,400 copies/mL. ‘Second line regimen’
referred to those on TDF/3TC/LPV/r, AZT/3TC/LPV/r and
AZT/ddI/LPV/r for adults according to the national ART
treatment guidelines 2004 and 2010 [12,16].
Statistical Analyses
For the analyses, patients were grouped into those who
transferred out and those who did not transfer-out. Categorical
variables were described by proportions and differences between
patient groups were compared using the x2 test and Fisher’s exact
test, as applicable. Numerical variables were assessed for normality
of distribution using Shapiro-Wilk test. Non-normally distributed
numerical variables were described by medians and inter-quartile
ranges and the differences between groups were compared using
Wilcoxon rank-sum test.
Six calendar periods of enrolment were defined as September
2002 to December 2004, followed by 5 calendar periods of 12
months each up to December 2009. The first calendar period
combined the first 2 years due to the small numbers of patients
enrolled in those years. The probability of transfer-out between
patients enrolled in successive calendar periods were estimated
using the Kaplan-Meier method, and comparisons were made
using the log-rank test. Analyses were stratified a priori according
to whether patients were ART-naı¨ve or ART non-naı¨ve since the
latter had by definition already transferred in to this cohort from
another treatment site and were therefore a highly selected
population. Cox proportional hazards analysis was used to
determine the risk factors for transferring out. Some risk factors
were chosen a priori from our previous research [7], while others
included ARV regimen at cohort entry and treatment naive status
at baseline. The proportional hazard assumption has been checked
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graphically using a log–log plot and the Schoenfeld residuals (tests
and graphs).
Basic descriptive statistics were used in the analyses of the most
recent characteristics prior to transfer. These analyses were
restricted to patients who transferred out after at least 1 year of
follow-up on ART at this service. A sub-analysis was performed
comparing the most recent viral load among ART-naı¨ve patients
transferring out with that at a comparable time point among
ART-naı¨ve patients not transferring out. A folder review was also
conducted to determine the reason why some ART-naı¨ve patients
transferred out with a viral load $1000 copies/mL.
Wald confidence limits were used for all multivariate models.
All statistical tests were 2-sided at alpha of 0.05. Stata statistical
software, version 10.0 was used for analyses (Stata Corporation,
College Station, TX).
Results
Patients and Follow-up
Between September 2002 and December 2009, a total of 4511
patients received ART (Figure 1). At baseline a majority (88.7%)
were ART-naı¨ve, the majority were female (67.2%) and the
median age was 29.0 years (interquartile range [IQR], 15.0–33.6).
Immunodeficiency was advanced with a median blood CD4
lymphocyte count of 109 cells/mL (IQR, 53–168). Disease was
categorized as WHO clinical stage III or IV in 73.1%.
The median duration of follow-up on ART was 2.5 years (IQR
1.2–4.3), with a minimum of 1.0 year and a maximum of 8.3 years.
A total of 12699 person-years of follow-up accrued during the
analysis period during which 597 (13.2%) patients transferred out.
In addition, 428 (9.5%) died, 996 (22.1%) were LTFU and 2490
(55.2%) were alive and receiving ART at the time data were
censored (Figure 1).
Rates and Proportions Transferring Out
Overall, the rate of transfer-out was 4.7 (95% CI 4.3–5.1)
patients per 100 person-years. The transfer-out rate was higher
among ART non-naı¨ve patients (9.11 per 100 person-years)
compared to those who were ART-naı¨ve (4.24 per 100 person-
years; P,0.0001). We used Kaplan-Meier analyses to examine
how the proportion of patients transferred out varied by
calendar period of enrolment. The proportion transferred-out
increased with more recent calendar periods of enrolment
(Figure 2A). Overall, the probability of transfer-out at 1 year
increased from 1.4% (95% CI 0.6%–3.0%) in the 2002–2004
cohort to 8.9% (95% CI 4.3%–7.8%) in the 2009 cohort.
Similar trends were observed in analyses stratifying by baseline
ART status (Figure 2B and Figure 2C), although overall
proportions were higher among the ART-non-naı¨ve patients.
Overall, the probability of transfer-out at 1 year was 18.3%
(95% CI, 12.1–27.3) among non-naı¨ve patients compared to
7.2% (95% CI, 5.4–9.5) among ART-naı¨ve patients (P,0.01).
Characteristics of Patients Transferring Out
We next examined the characteristics of patients who did and
those who did not transfer-out, stratifying by baseline ART status.
Among those who were ART-naı¨ve at baseline, patients who
transferred out were more likely to be female and younger
(Table 1). Among those who were ART non-naı¨ve at baseline, the
Figure 1. Description of patients starting ART at a community-based ART service in Gugulethu, Cape Town between September
2002 and December 2009.
doi:10.1371/journal.pone.0057907.g001
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characteristics of those who did and did not transfer-out were
broadly similar. An important observation was that of the non-
naı¨ve patients (ie those who transferred into the service already
receiving ART), only 69.4% had a viral load suppressed ,50
copies/mL and only 78.8% had a viral load suppressed ,400
copies/mL (Table 1).
Figure 2. Failure probability of transferring out by calendar period of enrolment a) overall patient cohort, b) among ART-naı¨ve and
c) ART non-naive patients attending a community-based clinic in Cape Town, South Africa.
doi:10.1371/journal.pone.0057907.g002
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Risk Factors for Transfer Out
We used Cox proportional hazards analysis to examine the risk
factors associated with transferring out (Table 2). In crude
analyses, risk (or hazard) of transfer-out was associated with
calendar year of enrolment, young age and being ART non-naı¨ve
at baseline. There was also an association with baseline CD4 cell
count and viral load although these were also strongly associated
with baseline ART status. In multivariate analysis, increased risk
of transfer-out was strongly associated with more recent calendar
period of enrolment and being ART non-naı¨ve at enrolment
(P,0.001) (Table 2).
Patient Characteristics at Time of Transfer Out
We next examined the characteristics of patients just prior to
transfer-out. We restricted this analysis to those transferring out
after at least one year of follow-up on ART to allow time for
virological suppression. The median duration on ART at the time
of transfer-out was 29.0 months (IQR 19.1–45.6) among patients
who were ART-naı¨ve at baseline compared to 24.7 months (IQR
17.3–37.4) among those who were non-naı¨ve at baseline (Table 3).
The proportions of these two groups of patients with CD4 cell
counts ,200 cells/mL were 20.1% and 13.4%, respectively. The
proportion of ART-naı¨ve and non-naı¨ve patients transferred out
with a viral load $1000 copies/mL was 20.7% and 15.6%,
respectively.
We next performed a sub-analysis restricted to those who were
ART-naı¨ve at baseline and compared the most recent viral loads
of patients who did and did not transfer-out after a similar ART
duration. Those transferring out were more likely to have a viral
load $1000 copies/mL in both unadjusted and adjusted analyses
(unadjusted risk ratio 1.72, 95% CI 1.29–2.30; adjusted risk ratio
1.67, 95% CI 1.24–2.24). Further investigation found that 44.1%
(95% CI, 32.0%–56.2%) of ART-naı¨ve patients transferring out
with a viral load $1000 copies/mL had not collected ART #12
weeks before the transfer-out date.
We then analyzed the viral loads of patients who were ART
non-naı¨ve at baseline and compared virological suppression rates
at baseline and at the time of transfer-out. Of those who had a viral
Table 2. Baseline patient characteristics associated with transferring out in a Multivariate Cox proportional Hazard Model.
Variables
Unadjusted Hazard
Ratio (95% CI) p-value
Adjusted Hazard
Ratio (95% CI) p-value
Calendar period of enrolment
Sept 2002–Dec 2004 (Ref) 1.00 – 1.00 –
Jan–Dec 2005 1.54 (1.10–2.16) 0.012 1.46 (1.04–2.07) 0.030
Jan–Dec 2006 2.41 (1.72–3.39) ,0.001 2.32 (1.64–3.28) ,0.001
Jan–Dec 2007 2.86 (2.01–4.08) ,0.001 2.58 (1.78–3.74) ,0.001
Jan–Dec 2008 2.81 (1.93–4.08) ,0.001 2.60 (1.76–3.84) ,0.001
Jan–Dec 2009 4.46 (3.05–6.51) ,0.001 4.00 (2.69–5.98) ,0.001
Gender
Female (ref) 1.00 – 1.00 –
Male 0.90 (0.75–1.07) 0.231 0.89 (0.73–1.08) 0.223
Age group
15–25 1.41 (1.06–1.88) 0.019 1.41 (1.04–1.91) 0.026
26–30 1.07 (0.86–1.37) 0.528 1.11 (0.86–1.42) 0.437
31–40 0.95 (0.77–1.17) 0.603 0.94 (0.76–1.17) 0.569
.41 1.00 – 1.00 –
Regimen at cohort entry
EFV-based (ref) 1.00 – 1.00 –
NVP- based 1.13 (0.95–1.34) 0.156 0.93 (0.77–1.13) 0.463
PI-based 1.38 (0.44–4.29) 0.583 0.84 (0.27– 2.64) 0.762
Treatment experience
ART-naı¨ve (ref) 1.00 – 1.00 –
ART non-naı¨ve 2.12 (1.71–2.62) ,0.001 1.96 (1.38–2.78) ,0.001
CD4 count at cohort entry
#100 1.00 – 1.00 –
101–200 0.91 (0.76–1.10) 0.347 0.88 (0.73–1.07) 0.204
$201 1.32 (1.06–1.64) 0.012 0.95 (0.73–1.24) 0.719
Viral load at cohort entry
,4 1.00 – 100 –
4–4.9 0.72 (0.57–0.90) 0.003 1.11 (0.82–1.49) 0.498
$5 0.83 (0.66–1.03) 0.090 1.28 (0.94–1.74) 0.116
CI, confidence interval.
doi:10.1371/journal.pone.0057907.t002
Transfers-Out in S. African ART Service
PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e57907
load $1000 copies/mL when they were transferred in [11.4%
(95% CI, 5.2%217.6%)] (Table 1), 66.7% (95% CI,
35.4%298.0%) of them subsequently transferred out with a viral
load $1000 copies/mL. Among this group, 50% (95% CI,
5.3%294.7%) were on first line treatment and the remaining 50%
(95% CI, 5.3%–94.7%) were on second-line treatment at the time
of transfer-out.
Discussion
In this large cohort study, we found that overall 13.2% of
patients transferred out during a median follow-up of 2.5 years but
that the proportion increased substantially with more recent
calendar periods of enrolment. Additional risk factors for transfer-
out were younger age (#25 years) and being non-naı¨ve to
antiretroviral therapy at baseline. A high proportion of patients
(20%) did not have a suppressed viral load just prior to transfer
and there was evidence that discontinuity of ART was common
around the time of transfer. Moreover, of patients on ART
transferring in to this service from elsewhere, many had detectable
viral loads, again suggesting discontinuity of medication supplies
or poor adherence.
Little is known about transfer-out rates in ART programmes in
sub-Saharan Africa. A study from Botswana reported a transfer
out rate of 5.2% after 1 year [9]. Our study documented a steady
increase in the proportion of patients transferring out, with this
proportion increasing from 1.4% to 8.9% at one year when
comparing the 2002–2004 cohort with the 2009 cohort. The
reasons for this phenomenon have not previously been documen-
ted. This is likely to reflect the availability of ART at increasing
numbers of primary health care centres nearer to patients’ homes
and increasing confidence and diminishing stigma among
individuals living with HIV, resulting in increased social accep-
tance and mobility. Other explanations may be that patients
wished to save on transport and time by attending facilities closer
to their homes [16] and that increasing congestion [7] and
depersonalization at this large clinic may have lowered the
threshold for patients requesting transfer-out. The rate of transfer-
out may have been further catalyzed by the policy of de-
centralization of ART to a wider network of primary health care
centres. The scale up of provider initiated counseling and testing
by the national TB program in 2005 [17], the implementation of
the national HIV counseling and testing policy guidelines in 2010
[18] and the change in national ART guidelines from an ART
eligibility of CD4 count 200 cells/mL to 350 cells/mL in early 2010
[19] all resulted in increased numbers of individuals accessing
ART, requiring further decentralisation. Lastly, this finding may
be due the out- migration of patients in the clinic mainly
originating from the Eastern Cape who had come to Cape Town
in search of better ART services, job opportunities, infrastructure
and quality of life.
Table 3. Characteristics at the time of transfer for both ART-naı¨ve and ART non-naive patients from a community-based ART
service in Gugulethu, Cape Town between September 2002 and December 2009.
Overall ART-naı¨ve at enrolment ART non-naı¨ve at enrolment
N=375 N=330 N=45
Variable Patients transferring out Patients transferring out
Time on ART at this service (months), median (IQR) 28.5 (18.6–44.4) 29.0 (19.1–45.6) 24.7 (17.3–37.4)
CD4 count at time of transfer (cells/mL)*
#100 24 (6.4) 21 (6.4) 3 (6.7)
101–200 48 (12.8) 45 (13.7) 3 (6.7)
.200 302 (80.8) 263 (79.9) 39 (86.7)
Viral load at the time of transfer (copies/mL), n (%){
$50 107 (28.6) 96 (29.0) 11 (24.4)
$400 84 (22.5) 76 (23.2) 7 (15.6)
$1000 76 (20.3) 68 (20.7) 7 (15.6)
Virological failure at the time of transfer, n (%)
Never 311 (82.9) 269 (81.5) 42 (93.3)
At any time point 35 (9.3) 61 (18.5) 3 (6.7)
#1 year 29 (7.7) 35 (10.6) 0 (0.0)
.1 year 26 (7.9) 3 (6.7)
Regimen at the time of transfer, n (%)
First line 327 (88.1) 289 (88.7) 38 (84.4)
Second line 44 (11.9) 37 (11.4) 7 (15.6)
Place of transfer
Cape Town 222 (59.2) 195 (59.1) 27 (60.0)
Other 153 (40.8) 135 (40.9) 18 (40.0)
All analyses restricted to patients that transferred out with at least 1 year of follow-up on ART at this service. This was done to allow sufficient time for virological
suppression as well as for blood samples to be drawn at most 3 times for CD and VL measurements.
*CD4 cell count data at the time of transfer were available for 329 ART naı¨ve and 45 ART non naı¨ve patients.
{Viral load data at the time of transfer were available for 329 ART naı¨ve and 45 ART non-naı¨ve patients.
doi:10.1371/journal.pone.0057907.t003
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The escalating rates of transfer-out over time presents a chal-
lenge to the health care system and to accurate documentation of
outcomes and programme performance. There is a need for
reliable tracking systems that can ascertain whether transfers of
care have been successful. Although such patient tracking systems
exist in some sites offering ART, there are yet to be implemented
across sites on a country-wide basis (including at our ART service).
Moreover, the implementation of such patient tracking systems in
many other sub-Saharan countries has been challenging [2].
Younger age and being non-naı¨ve to ART at baseline were
associated with higher risk of transferring out. It is possible that
younger people attending the clinic are more likely to move to
other areas in search of employment, better opportunities and
better social support networks. Opportunity, poverty or poor social
support networks may therefore dictate transfer-out. Our data
suggest that a proportion of those patients who were non-naı¨ve to
ART at baseline (ie those who had already transferred out from
another clinic and enrolled in this clinic) serially transfer between
clinics and that a significant proportion had unsuppressed viral
loads. These may represent an important sub-group of patients
with poor adherence, which may have important underlying
factors such as social stigma and non-disclosure.
Achieving and sustaining viral suppression is key in the delivery
of long-term ART. Our findings are of real concern that
a substantial proportions of patients had viral loads .1000
copies/mL around the time of both transfer-out and transfer-in to
this ART service. This could be due to patients who move or gain
employment elsewhere and who subsequently struggle to attended
scheduled appointments, before eventually requesting transfer to
another facility. This may also indicate poor adherence, with
treatment interruption often occurring prior to the date of transfer.
Alternatively, this could indicate high rates of viral resistance
(transmitted or acquired). Studies have shown that factors such as
ART adverse effects, substance abuse, clinical depression and
clinicians lack of experience to treat HIV disease are all associated
with increased risk of an unsuppressed viral load [12,20–23]. The
specific factors relevant in this cohort need to be understood
through further research and appropriate interventions need to be
identified and implemented. From our own experience, we
speculate that intensive counselor-driven interventions addressing
poor adherence, including addressing social-related factors (i.e.
substance abuse, clinical depression, encouraging patients to join
social support groups) may be necessary.
The strengths of the study include the study of a very well
characterized cohort with careful patient follow-up, including 4-
monthly CD4 cell count and viral load measurements. The patient
within this township cohort are typical of large public sector ART
cohorts throughout Cape Town, South Africa. Study limitations
include selection bias due to missing information in multivariate
analysis may exist although this is likely to be minimal in view of
the completeness of the data collected and that the few missing
observations were random. This was an observational study that
used data collected from routine program evaluation which are
limited by operational constraints. The contribution of socioeco-
nomic status of ART patients on transfer out rates could not be
ascertained from our data. However, the community in which the
clinic operated has a high unemployment rate in general and
therefore serves mainly low-income ART patients. This manu-
script does not deal with silent or unnoticed transfers-out and this
may underestimate our finding of increased transfer-out with
yearly cohorts. We were not able to ascertain the final outcomes of
patients who transferred out from this service.
Conclusions
In summary, during ongoing scale-up of ART, increasing
proportions of patients are transferring between ART services and
the reasons for this are not yet well understood. It is of real
concern that approximately one fifth of patients had viral loads of
.1000 copies/mL around the time of transfer, suggesting the need
for careful adherence counseling and assessment of medication
supplies among those planning to transfer. Furthermore, in-
formation systems need to be developed that can track patients, to
assess successful transfer of care between health care facilities and
to provide accurate programme outcome data.
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